Psoriatic arthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-17 4
• TNF 4
• IL-23 0
• JAK 1
• GLP-1 3
• TYK2 0
• IL-1 0
• SGLT2 0
• APOE 0
• BRCA2 0
• CD19 0
• FGFR 0
• G6PD 0
• GIP 1
• IL-13 0
• NLRP3 0
• NRF2 0
• PDE4 0
• STAT3 0

24 of 692 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-RIA

  iPROLEPSIS: PSORIATIC ARTHRITIS INFLAMMATION EXPLAINED THROUGH MULTI-SOURCE DATA ANALYSIS GUIDING A NOVEL PERSONALISED DIGITAL CARE ECOSYSTEM

  Aristotelio Panepistimio Thessalonikis· Thessaloniki, Greece· EU contribution €6,483,091· until Dec 2027· 9 countries

• European Commission (Horizon 2020) · RIA

  Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €10,210,993· until Jun 2027· 11 countries

2 of 2 running projects, newest first. Listed amounts together: €16.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

  NCT06431750· Novartis Pharmaceuticals· Updated 7 Aug 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

  NCT06522035· Enlivex Therapeutics Ltd.· Updated 13 Apr 2026

  “reprioritization”Registry text, quoted unchanged. Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Updated 27 Mar 2026

  “Abandonment of the study project”Registry text, quoted unchanged. Source

• Withdrawn

  Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

  NCT07255781· University of California, San Diego· Updated 23 Feb 2026

  “The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.”Registry text, quoted unchanged. Source

• Terminated

  Psoriatic Arthritis Study of Izokibep

  NCT05623345· ACELYRIN Inc.· Updated 23 May 2025

  “Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.”Registry text, quoted unchanged. Source

• Terminated

  Quantitative Ultrasound of the Enthesis in Fibromyalgia and Psoriatic Arthritis

  NCT05447741· Centre hospitalier de l'Université de Montréal (CHUM)· Updated 25 Feb 2025

  “The recruitment and examination of participants were halted prematurely due to depleted funds.”Registry text, quoted unchanged. Source

• Terminated

  VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

  NCT05715125· Ventyx Biosciences, Inc· Updated 27 Dec 2024

  “sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

  NCT06715254· Novartis Pharmaceuticals· Updated 4 Dec 2024

  “Due to the limited availability of eligible patients who met the study's criteria, as well as there has not been a case of tuberculosis, the study was terminated early.”Registry text, quoted unchanged. Source

• Terminated

  Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

  NCT05511519· Aclaris Therapeutics, Inc.· Updated 27 Nov 2024

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

  NCT05499416· Innovaderm Research Inc.· Updated 15 Mar 2023

  “Sponsor decision.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Takeda· Source

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Source

• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Takeda· Source

• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· MoonLake Immunotherapeutics AG· Source

• Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

  NCT06751238· Novartis Pharmaceuticals· Source

• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

  NCT04638647· Novartis Pharma AG· Source

• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

  NCT06865105· AbbVie· Source

• A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

  NCT07801495· Novartis Pharmaceuticals· Source

• Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)

  NCT07923773· Novartis Pharmaceuticals· Source

• Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

  NCT07111494· Medical College of Wisconsin· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• Gene Expression Profiling 9
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 3
• Flow Cytometry 2
• Magnetic Resonance Imaging 23
• Machine Learning 8
• Cohort Studies 22
• Genome-Wide Association Study 9

• Extracapsular and joint-dominant hand and wrist MRI patterns in psoriatic and rheumatoid arthritis: an exploratory case-control study.

  Front Immunol, Oct 2026

• Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study.

  Arthritis Res Ther, Aug 2026

• Bilateral knee lipoma arborescens mimicking persistent inflammatory arthritis in a patient with psoriatic arthritis.

  BMJ Case Rep, Jul 2026

• Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial.

  Rheumatology (Oxford), Jun 2026

• Role of the S1P/S1PR axis in inflammation and structural damage in psoriatic arthritis: a cross-sectional study with clinical, biochemical and imaging correlation.

  RMD Open, Jun 2026

• CT and MRI features of SAPHO syndrome: a report of 6 cases.

  BMC Musculoskelet Disord, Jun 2026

• Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis.

  Ann Rheum Dis, May 2026

• Feasibility of Ultrashort Echo Time MR Imaging for the Detection of Subclinical Achilles Enthesitis in Psoriasis and Psoriatic Arthritis.

  Magn Reson Med Sci, May 2026

• Diagnostic Algorithm for Axial Involvement in Psoriatic Arthritis.

  Dokl Biochem Biophys, Mar 2026

• Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

  Ann Rheum Dis, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.